Literature DB >> 2502917

Gaucher disease: molecular heterogeneity and phenotype-genotype correlations.

B Theophilus1, T Latham, G A Grabowski, F I Smith.   

Abstract

Gaucher disease (GD) is the most prevalent lysosomal storage disease. This autosomal recessive trait results from the defective activity of acid beta-glucosidase (beta-Glc). Four different exonic point mutations have been identified as causal alleles for GD. To facilitate screening for these alleles, assays were developed using allele-specific oligonucleotide hybridization to amplified genomic DNA sequences. Specifically, intron bases flanking exons 5, 9, and 10 were determined, and conditions for PCR amplification of these exons were obtained. Two different procedures were developed to distinguish signals obtained from the structural beta-Glc gene exons and those from the pseudogene. These procedures were used to determine the distribution of all known GD alleles in a population of 44 affected patients of varying phenotypes and ethnicity. The high frequency of one of the exon 9 mutations in Ashkenazi Jewish GD type 1 patients was confirmed, and, in addition, this mutation was present in ethnically diverse non-Jewish type 1 GD patients. Homozygotes (N = 5) for this allele were midly affected older individuals, and this mutant allele was not found in any patient with neuronopathic disease. The exon 10 mutation was confirmed as the predominant allele in types 2 and 3 GD. However, several type 1 GD patients, including one of Ashkenazi-Jewish heritage, also were heterozygous for this allele. The presence of this allele in type 1 patients did not correlate with the severity of clinical symptoms. The second exon 9 mutation and the exon 5 mutation were rare, since they occurred only heterozygously either in one type 2 GD patient or in two related Ashkenazi-Jewish GD patients, respectively. Although most GD patients (38 of 44) had at least one of the known mutant alleles, 57% were heterozygotes for only one of these mutations. Fourteen percent of patients were negative for all mutations. A total of 73% of GD patients had at least one unknown allele. The varying clinical phenotypes and ethnic origins of these incompletely characterized patients suggest that multiple other GD alleles exist.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502917      PMCID: PMC1683351     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  16 in total

1.  Structural analysis of the human glucocerebrosidase genes.

Authors:  O Reiner; M Wigderson; M Horowitz
Journal:  DNA       Date:  1988-03

2.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

3.  Characterization of mutations in Gaucher patients by cDNA cloning.

Authors:  M Wigderson; N Firon; Z Horowitz; S Wilder; Y Frishberg; O Reiner; M Horowitz
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

4.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

5.  The human glucocerebrosidase gene and pseudogene: structure and evolution.

Authors:  M Horowitz; S Wilder; Z Horowitz; O Reiner; T Gelbart; E Beutler
Journal:  Genomics       Date:  1989-01       Impact factor: 5.736

6.  Supercoil sequencing: a fast and simple method for sequencing plasmid DNA.

Authors:  E Y Chen; P H Seeburg
Journal:  DNA       Date:  1985-04

7.  Gaucher disease type 1: cloning and characterization of a cDNA encoding acid beta-glucosidase from an Ashkenazi Jewish patient.

Authors:  P N Graves; G A Grabowski; R Eisner; P Palese; F I Smith
Journal:  DNA       Date:  1988-10

8.  Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.

Authors:  G A Grabowski; T Dinur; K M Osiecki; J R Kruse; G Legler; S Gatt
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

9.  Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.

Authors:  G A Grabowski; J Goldblatt; T Dinur; J Kruse; L Svennerholm; S Gatt; R J Desnick
Journal:  Am J Med Genet       Date:  1985-07

10.  Studies on transformation of Escherichia coli with plasmids.

Authors:  D Hanahan
Journal:  J Mol Biol       Date:  1983-06-05       Impact factor: 5.469

View more
  32 in total

1.  Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.

Authors:  Ying Sun; Benjamin Liou; You-Hai Xu; Brian Quinn; Wujuan Zhang; Rick Hamler; Kenneth D R Setchell; Gregory A Grabowski
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  High level transcription of the glucocerebrosidase pseudogene in normal subjects and patients with Gaucher disease.

Authors:  J Sorge; E Gross; C West; E Beutler
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

3.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.

Authors:  A Zimran; T Gelbart; B Westwood; G A Grabowski; E Beutler
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

4.  Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.

Authors:  J J MacKenzie; D Amato; J T Clarke
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

5.  An unusual insertion/deletion in the gene encoding the beta-subunit of propionyl-CoA carboxylase is a frequent mutation in Caucasian propionic acidemia.

Authors:  T Tahara; J P Kraus; L E Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

6.  Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells.

Authors:  P H Correll; J K Fink; R O Brady; L K Perry; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  The molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes angiokeratoma corporis diffusum with glycopeptiduria.

Authors:  A M Wang; T Kanzaki; R J Desnick
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

8.  Phenotypic and genotypic heterogeneity in gaucher disease: Implications for genetic counseling.

Authors:  E Sidransky; E I Ginns
Journal:  J Genet Couns       Date:  1994-03       Impact factor: 2.537

9.  Niemann-Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant.

Authors:  S Victor; J B S Coulter; G T N Besley; I Ellis; R J Desnick; E H Schuchman; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.

Authors:  Ying Sun; Benjamin Liou; Brian Quinn; Huimin Ran; You-Hai Xu; Gregory A Grabowski
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.